ProCE Banner Activity

My Take: Why and How We Should Assess Fibrosis in Patients With HBV

Clinical Thought
Determining the level of fibrosis is key in evaluating patients for HBV treatment candidacy. How, when, and why should we incorporate fibrosis assessments into clinical practice? Here’s my take.

Released: February 18, 2021

Expiration: February 17, 2022

Share

Faculty

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from:

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from Aligos, Gilead Sciences, and Janssen and funds for research support from Assembly, Bristol-Myers Squibb, Eiger, Gilead Sciences, and Janssen.